Skip to main content
Premium Trial:

Request an Annual Quote

CareDx Receives CE Mark for AlloSeq cfDNA Kit

NEW YORK – CareDx said on Friday that it has received the CE mark for its AlloSeq cfDNA kit, making it available to transplant patients and clinicians in Europe.

AlloSeq cfDNA is a kit-based product that is used to quantify the level of donor-derived cell-free DNA in transplant recipients in order to measure graft health, and is run on next generation sequencing platforms. 

"AlloSeq cfDNA provides a measure of organ injury that can help monitor transplant patient outcomes. With the CE mark, we can begin our pan-European dd-cfDNA registry and studies with CareDx," Phil Mason, a transplant nephrologist at the NHS's Oxford University Hospitals, said in a statement.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.